Literature DB >> 16496357

Prognostic factors of myxofibrosarcomas: implications of margin status, tumor necrosis, and mitotic rate on survival.

Ching-Nan Lin1, Shin-Cheng Chou, Chien-Feng Li, Kun-Bow Tsai, Wen-Chung Chen, Ching-Yeh Hsiung, Cheng-Fang Yen, Hsuan-Ying Huang.   

Abstract

BACKGROUND: Myxofibrosarcomas (MFS) are characterized by tumor progression with increased metastases after local recurrences (LR). Few series had appropriately addressed what parameters independently affect prognosis.
METHODS: Seventy primary localized MFS were analyzed for local recurrence-free survival (LRFS), metastasis-free survival (MeFS), and disease-specific survival (DSS). Follow-up was obtained in 61 cases.
RESULTS: Thirty-eight males and 32 females had primary tumors ranging from 1.5 to 24 cm. Thirty and 40 tumors were superficial and deep, respectively, with 26 cases (38%) having positive margins. The 5-year LRFS-, MeFS-, and DSS-rates were 30%, 60%, and 73%. Positive margins (P = 0.0003) were the only inferior LRFS predictor. High grade (FNCLCC 2 and 3) was a negative factor of both MeFS (P = 0.0078) and DSS (P = 0.0174), and high stage (AJCC stage 3) was predictive of MeFS (P = 0.0470). However, both grading and staging were not prognostically independent. In multivariate analyses, mitoses >or=20/10 HPF (P = 0.0009, RR = 9.71) and positive margins (P = 0.0203, RR = 4.27) were independent adverse DSS predictor. However, tumor necrosis >or=10% (P = 0.0092, RR = 3.91) independently correlated with worse MeFS, together with mitoses >or=20/10 HPF (P = 0.0176, RR = 3.80) and positive margins (P = 0.0121, RR = 3.41).
CONCLUSIONS: Margin status and histologic property both affect the prognosis of MFS. The former correlates with improved LRFS and translates into final survival benefits. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2006        PMID: 16496357     DOI: 10.1002/jso.20425

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  15 in total

1.  An analysis of factors related to the tail-like pattern of myxofibrosarcoma seen on MRI.

Authors:  Kazutaka Kikuta; Daisuke Kubota; Akihiko Yoshida; Hideo Morioka; Yoshiaki Toyama; Hirokazu Chuuman; Akira Kawai
Journal:  Skeletal Radiol       Date:  2014-08-30       Impact factor: 2.199

2.  Establishment and characterization of a novel cell line, NCC-MFS1-C1, derived from a patient with myxofibrosarcoma.

Authors:  Fusako Kito; Rieko Oyama; Marimu Sakumoto; Kumiko Shiozawa; Zhiwei Qiao; Shunichi Toki; Akihiko Yoshida; Akira Kawai; Tadashi Kondo
Journal:  Hum Cell       Date:  2019-02-08       Impact factor: 4.174

Review 3.  Giant myxofibrosarcoma of the orbit: a rare case and a review of the literature.

Authors:  Rachna Meel; Gautam Lokdarshi; Seema Kashyap; Sanjay Sharma
Journal:  BMJ Case Rep       Date:  2016-06-13

Review 4.  Soft tissue sarcomas with complex genomic profiles.

Authors:  Louis Guillou; Alain Aurias
Journal:  Virchows Arch       Date:  2010-02       Impact factor: 4.064

Review 5.  [Pleomorphic high-grade soft tissue sarcomas: is the subclassification up to date?].

Authors:  G Mechtersheimer; M Renner; R Penzel; P Schirmacher
Journal:  Pathologe       Date:  2011-02       Impact factor: 1.011

6.  Prognostic factors and outcomes of patients with myxofibrosarcoma.

Authors:  G Petur Nielsen; John T Mullen; Nicole J Look Hong; Francis J Hornicek; Kevin A Raskin; Sam S Yoon; Jackie Szymonifka; Beow Yeap; Yen-Lin Chen; Thomas F DeLaney
Journal:  Ann Surg Oncol       Date:  2012-08-14       Impact factor: 5.344

Review 7.  Local recurrence of soft-tissue sarcoma: issues in imaging surveillance strategy.

Authors:  Nisreen S Ezuddin; Juan Pretell-Mazzini; Raphael L Yechieli; Darcy A Kerr; Breelyn A Wilky; Ty K Subhawong
Journal:  Skeletal Radiol       Date:  2018-05-21       Impact factor: 2.199

8.  Epitheloid myxofibrosarcoma of the parotid gland.

Authors:  B Srinivasan; M Ethunandan; K Hussain; V Ilankovan
Journal:  Case Rep Pathol       Date:  2011-09-13

9.  Prognostic and survival factors in myxofibrosarcomas.

Authors:  Varun Dewan; Anna Darbyshire; Vaiyapuri Sumathi; Lee Jeys; Robert Grimer
Journal:  Sarcoma       Date:  2012-06-11

10.  The novel myxofibrosarcoma cell line MUG-Myx1 expresses a tumourigenic stem-like cell population with high aldehyde dehydrogenase 1 activity.

Authors:  Birgit Lohberger; Nicole Stuendl; Elisabeth Wolf; Bernadette Liegl-Atzwanger; Andreas Leithner; Beate Rinner
Journal:  BMC Cancer       Date:  2013-12-01       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.